Table 1.
Baseline patient and disease characteristics (N = 83).
| Characteristic | Values* |
|---|---|
| Sex | |
| Male | 56 (67.5) |
| Female | 27 (32.5) |
| Age | |
| Median (range), years | 63 (25-88) |
| <65 years | 46 (55.4) |
| ≥65 years | 37 (44.6) |
| ECOG performance status | |
| 0 | 27 (32.5) |
| 1 | 55 (66.3) |
| 2 | 1 (1.2) |
| Tumor cell PD-L1 expressiona | |
| ≥1% | 54 (65.1) |
| <1% | 21 (25.3) |
| Not available | 8 (9.6) |
| EGFR mutation statusb | |
| Wild type | 47 (85.5) |
| Mutated | 4 (7.3) |
| Not available | 4 (7.3) |
| Tumor histology | |
| Nonsquamousc | 55 (66.3) |
| Squamous cell carcinoma | 28 (33.7) |
| Number of prior anticancer regimensd | |
| 2 | 21 (25.3) |
| 3 | 26 (31.3) |
| ≥4 | 36 (43.4) |
| Type of prior anticancer therapy for metastatic or locally advanced disease | |
| Anti-PD-(L)1 | 83 (100) |
| Cytotoxic therapy | 79 (95.2) |
| Endocrine therapy | 1 (1.2) |
| Monoclonal antibody therapy | 19 (22.9) |
| Small molecules | 18 (21.7) |
| Immunotherapy other than anti-PD-(L)1 | 3 (3.6) |
| Other | 7 (8.4) |
| Last anticancer therapy before the study | |
| Anti-PD-(L)1 | 43 (51.8) |
| Cytotoxic therapy | 36 (43.3) |
| Monoclonal antibody therapy | 4 (4.8) |
| Small molecules | 5 (6.0) |
| Immunotherapy other than anti-PD-(L)1 | 2 (2.4) |
| Other | 1 (1.2) |
| Best objective response to last anticancer regimen | |
| Complete response | 0 |
| Partial response | 10 (12.0) |
| Stable disease | 30 (36.1) |
| Progressive disease | 41 (49.4) |
| Not assessable | 1 (1.2) |
| Not available | 1 (1.2) |
| Prior PD-(L)1 treatment status | |
| Acquired resistance | 45 (54.2) |
| Primary refractory | 35 (42.2) |
| Not available | 3 (3.6) |
*Values are shown as n (%) unless otherwise indicated.
aPD-L1 expression was determined by immunohistochemistry using a proprietary assay (Dako PD-L1 IHC 73-10 pharmDx; Dako, Carpinteria, CA).28
bPercent was calculated based on the number of patients with nonsquamous histology (n = 55).
cNonsquamous histology includes adenocarcinoma (n = 50), large cell (n = 1), non-small cell carcinoma (n = 1), epidermoid sarcoma (n = 1), epidermoid carcinoma (n = 1), and sarcomatoid carcinoma (n = 1).
dPrior therapy in any setting (neoadjuvant, adjuvant, locally advanced, and metastatic disease).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death 1 ligand 1.